Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Metaxalone clinical trials

Also listed in trial records as M640, Skelaxin
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA register that name Metaxalone as an intervention. Synced 10 Nov 2026
2Current trials
2Recruiting now
1Lead sponsor
1Country register
At a glance

Metaxalone is named as an intervention in 2 current clinical trials in our USA register. 2 are recruiting patients now. All registered phases are Phase 4. The lead sponsor is Primus Pharmaceuticals. The most-studied condition is Sciatica Acute.

Where Metaxalone is approved

All regulators →

Of the three regulators tracked here, the first to approve Metaxalone was the US, on 13 Aug 1962.

USUnited States (FDA)
13 Aug 1962
Skelaxin
NDA013217 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
No centralised EU authorisation (it may be authorised nationally)
First centralised authorisation
CACanada (Health Canada)
No new-drug Notice of Compliance since 1994
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Metaxalone patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Metaxalone, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Metaxalone
  • 2 listed patents; the last listed expires 14 May 2043 (US 12485111).
See the Orange Book listing for NDA 022503

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Metaxalone

All medicines →
ENNHS England
Not dispensed in the community in England in the last 12 months under this name
Net ingredient cost, community prescriptions
USUS Medicaid
$12.0m
27,998 prescriptions in 2025 · Metaxalone
+621% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

Patient leaflets for Metaxalone

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Metaxalone

ChEMBL
CHEMBL1079604
DrugBank
DB00660
PubChem CID
15459
CAS number
1665-48-1
FDA UNII
1NMA9J598Y
Wikidata
Q6823309
Wikipedia
Metaxalone

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting2100%

Trials by phase

  • Phase 42100%
01

Clinical trials of Metaxalone

2 trials
StudyPhaseStatusLead sponsorRegisters
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177 · Sciatica Acute, Lumbar Spinal Stenosis
Phase 4 Recruiting Primus Pharmaceuticals USA
Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer
NCT07801066 · Healthy Participants
Phase 4 Recruiting Primus Pharmaceuticals USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Metaxalone

3 conditions
Sciatica Acute1Lumbar Spinal Stenosis1Healthy Participants1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Primus Pharmaceuticals2
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA22

A trial with sites in more than one country appears in each of those registers.

05

Questions about Metaxalone trials

How many clinical trials are testing Metaxalone?

2 current trials in our USA register name Metaxalone (also registered as M640) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Metaxalone trials recruiting patients?

Yes. 2 of the 2 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Metaxalone clinical trials?

The lead sponsor is Primus Pharmaceuticals. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Metaxalone works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Metaxalone works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Metaxalone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.